2020年欧洲肿瘤内科学会（ESMO）年会将于9月19~21日以线上会议形式举行，在全球疫情形式回暖之际，下半年的肿瘤学术交流也开始全面复苏。本文总结泌尿男生殖系肿瘤领域的重磅研究如下。
一、免疫挺进一线，ADC后起之秀
在9月19日和9月21日举行的三场泌尿生殖系统肿瘤“Proffered Paper”专场中，PD-1/L1免疫治疗依然在肾癌、尿路上皮癌领域中一骑绝尘，或单药、或联合挺进一线治疗；而在免疫治疗失败后的选择中也有了新药布局，比如刚刚在三阴性乳腺癌中崭露头角的ADC新药Sacituzumab-Govitecan也在尿路上皮癌中进行探索。
LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
帕博利珠单抗联合化疗与单纯化疗作为晚期尿路上皮癌一线治疗的比较：KEYNOTE-361
时间：9月19日16:20 - 16:32
讲者：Ajjai Alva (Ann Arbor， MI， United States of America)
697O - A phase III， randomized， open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable， locally advanced or metastatic urothelial carcinoma (DANUBE)
度伐单抗（抗PD-L1）±tremelimumab（抗CTLA4）对比标准化疗作为不可切除、局部晚期或转移性尿路上皮癌一线治疗的Ⅲ期、随机、开放标签研究
时间：9月19日16:32 - 16:44
讲者：Thomas B. Powles (London， United Kingdom)
LBA24 - TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer (mUC) That Has Progressed After Platinum (PLT) and Checkpoint Inhibitors (CPI)
TROPHY-U-01研究队列1最终结果：Sacituzumab-Govitecan（一种新型ADC药物）治疗铂和免疫检查点抑制剂后进展的转移性尿路上皮癌的2期研究
时间：9月19日17:04 - 17:16
讲者：Yohann Loriot (Villejuif， France)
698O - Patient-reported outcomes (PROs) from IMvigor130: A global， randomised， partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
来自IMvigor130的患者报告结果（PROs）：一项关于阿替利珠单抗（atezo）+铂类化疗（PBC）对比安慰剂（PBO）+PBC治疗先前未经治疗的局部晚期或转移性尿路上皮癌（mUC）的全球、随机、部分盲法的Ⅲ期研究
时间：9月19日17:16 - 17:28
讲者：Aristotelis Bamias (Athens， Attiki， Greece)
699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
阿维鲁单抗一线维持+最佳支持治疗（BSC）与单纯BSC治疗晚期尿路上皮癌（UC）的比较：临床结果与探索性生物标志物的关系
时间：9月19日17:28 - 17:40
讲者：Srikala Sridhar (Toronto， ON， Canada)
700O - Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
肾ccRCC免疫分类（KIC）提高了T效应器（Teff）和血管生成（Angio）信号对纳武利尤单抗（N）反应的预测价值
时间：9月21日16:20 - 16:32
讲者：Maxime Meylan (Paris， France)
701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
847例转移性肾细胞癌（mRCC）患者的循环肿瘤DNA（ctDNA）评估以及与组织检测的一致性评估
时间：9月21日16:32 - 16:44
讲者：Zeynep B. Zengin (Duarte， United States of America)
702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
卡博替尼（C）联合阿替利珠单抗（A）作为晚期肾透明细胞癌（ccRCC）的一线治疗：来自COSMIC-021研究的结果
时间：9月21日17:04 - 17:16
讲者：Sumanta Pal (Duarte， United States of America)
LBA25 - Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial.
应用纳武利尤单抗（N）和伊匹木单抗或VEGFR酪氨酸激酶抑制剂（TKI）治疗转移性肾癌（m-ccRCC）的2期生物标记物驱动试验结果：BIONIKK试验
时间：9月21日17:16 - 17:28
讲者：Yann Vano (Paris， France)
609O - Results from a phase I study of AMG 160， a half-life extended (HLE)， PSMA-targeted， bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
来自Ⅰ期研究AMG 160的结果：一种半衰期延长（HLE）、PSMA靶向的双特异性T细胞接合器（BiTE®）免疫治疗转移性去势抵抗前列腺癌（mCRPC）
时间：9月21日14:25 - 14:37
讲者：Ben Tran (Melbourne， Australia)
611O - Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)
醋酸阿比特龙联合泼尼松龙治疗激素性前列腺癌（PCa）：STAMPEDE随机试验中转移（M1）患者的长期结果（NCT00268476）
时间：9月21日14:57 - 15:09
讲者：Nicholas D. James (London， United Kingdom)
二、新老同台竞技，再现复旦方案
在9月18日释放的“Mini oral”环节中，HIF-2α抑制剂、RTK抑制剂、新型口服微管蛋白抑制剂、疫苗疗法等一众新药相继登台亮相。与此同时，二甲双胍的“老生”代表也踏足前列腺癌，呈现一派新老同台竞技的火热场面。更值得骄傲的是，复旦大学附属肿瘤医院戴波教授汇报的寡转移性前列腺癌原发灶局部治疗的Ⅱ期研究也入选了该环境，以口头报告（MO）形式向世界传递中国之声。
LBA26 - Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau (VHL) Disease–Associated Clear Cell Renal Cell Carcinoma (ccRCC): Update on RCC and Non-RCC Disease
口服HIF-2α抑制剂MK-6482治疗Von-Hippel-Lindau（VHL）相关肾透明细胞癌（ccRCC）的2期研究：RCC和非RCC疾病的更新
讲者：Ramaprasad Srinivasan (Bethesda， United States of America)
703MO - An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution
肾癌进化过程中空间动力学和基因组改变的综合研究
讲者：Yue Zhao (London， United Kingdom)
704MO - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
阿维鲁单抗一线（1L）维持+最佳支持治疗（BSC）对比单用1L化疗（CTx）治疗晚期尿路上皮癌（UC）：来自JAVELIN Bladder 100的亚组分析
讲者：Petros Grivas (Seattle， United States of America)
705MO - Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve， platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
Sitravatinib（RTK抑制剂）联合纳武利尤单抗在未经检查点抑制剂（CPI）、但经过多重铂类治疗的晚期或转移性尿路上皮癌（UC）患者中具有临床活性
讲者：Pavlos Msaouel (Houston， United States of America)
706MO - Association between human papillomavirus (HPV) infection and outcome of perioperative nodal radiotherapy for penile carcinoma
人乳头瘤病毒（HPV）感染与阴茎癌围手术期淋巴结放疗预后的关系
讲者：Andrea Necchi (Milan， Italy)
707MO - Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre
大型四级学术中心治疗的转移性阴茎癌患者的纵向队列分析
讲者：Wing Kin Liu (London， United Kingdom)
708MO - Metachronous contralateral testicular cancer in the cisplatin era: A population-based cohort study
顺铂时代的异时性对侧睾丸癌：一项基于人群的队列研究
讲者：Ragnhild Hellesnes (Tromso， Norway)
612MO - Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
前列腺癌患者体细胞改变的临床影响，有或没有已知的胚系BRCA1/2突变：PROREPAIR研究结果
讲者：Rebeca Lozano Mejorada (Madrid， Spain)
614MO - Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects
卡巴他赛（CBZ）在转移性抗去势前列腺癌（mCRPC）伴和不伴DNA损伤修复（DDR）缺陷男性患者中的治疗活性
讲者：Mihaela Aldea (Villejuif， France)
LBA22 - Imaging based PCa screening among BRCA mutation carriers – results from the first round of screening
基于BRCA突变携带者中前列腺癌筛查的成像——第一次筛查的结果
讲者：David Margel (Petah Tikva， Israel)
615MO - Phase Ib/II study of VERU-111， novel， oral tubulin inhibitor， in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent
新型口服微管蛋白抑制剂VERU-111在男性转移性去势抵抗前列腺癌（mCRPC）中的Ⅰb/Ⅱ期研究
讲者：Mark Markowski (Baltimore， MD， United States of America)
616MO - Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)
BN-brachyury（一种新型疫苗）+bintrafusp-alfa（TGF-b/PD-L1双抗）+N-803治疗去势耐药前列腺癌（CRPC）的疗效：来自QuEST1试验的初步分析结果
讲者：Jason M. Redman (Bethesda， United States of America)
617MO - Repurposing metformin as an anticancer drug: Preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)
二甲双胍作为抗癌药物的老药新用：晚期前列腺癌随机对照试验的初步结果
讲者：Reham Alghandour (Mansoura， Egypt)
618MO - Local therapy to the primary tumour for newly diagnosed， oligo-metastatic prostate cancer: A prospective randomized， phase II， open-label trial
新诊断寡转移性前列腺癌原发肿瘤的局部治疗：一项前瞻性随机、开放标签的Ⅱ期试验
讲者：戴波（复旦大学附属肿瘤医院）
京公网安备 11010502033352号